132 related articles for article (PubMed ID: 7298112)
1. Plasma concentration and acetylator phenotype determine response to oral hydralazine.
Shepherd AM; McNay JL; Ludden TM; Lin MS; Musgrave GE
Hypertension; 1981; 3(5):580-5. PubMed ID: 7298112
[TBL] [Abstract][Full Text] [Related]
2. Acetylator phenotype and the antihypertensive response to hydralazine.
Jounela AJ; Pasanen M; Mattila MJ
Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
[TBL] [Abstract][Full Text] [Related]
3. Hydralazine kinetics after single and repeated oral doses.
Shepherd AM; Ludden TM; McNay JL; Lin MS
Clin Pharmacol Ther; 1980 Dec; 28(6):804-11. PubMed ID: 7438695
[TBL] [Abstract][Full Text] [Related]
4. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
[TBL] [Abstract][Full Text] [Related]
5. Effect of oral dose size on hydralazine kinetics and vasodepressor response.
Shepherd AM; Irvine NA; Ludden TM; Lin MS; McNay JL
Clin Pharmacol Ther; 1984 Nov; 36(5):595-600. PubMed ID: 6488679
[TBL] [Abstract][Full Text] [Related]
6. Relation of hydralazine plasma concentration to dosage and hypotensive action.
Zacest R; Koch-Weser J
Clin Pharmacol Ther; 1972; 13(3):420-5. PubMed ID: 5026380
[No Abstract] [Full Text] [Related]
7. Synthesis, formulation, and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone in two healthy volunteers.
Reece PA; Stafford I; Prager RH; Walker GJ; Zacest R
J Pharm Sci; 1985 Feb; 74(2):193-6. PubMed ID: 3989691
[TBL] [Abstract][Full Text] [Related]
8. Variability of plasma hydralazine concentrations in male hypertensive patients.
Ludden TM; McNay JL; Shepherd AM; Lin MS
Arthritis Rheum; 1981 Aug; 24(8):987-93. PubMed ID: 7284051
[TBL] [Abstract][Full Text] [Related]
9. Possible optimization of sulphadimidine dosage for acetylator phenotyping.
Hombhanje F
Jpn J Pharmacol; 1991 Aug; 56(4):531-4. PubMed ID: 1744992
[TBL] [Abstract][Full Text] [Related]
10. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.
Rashid JR; Kofi-Tsepko ; Juma FD
East Afr Med J; 1992 Jul; 69(7):406-8. PubMed ID: 1396201
[TBL] [Abstract][Full Text] [Related]
11. Effect of food on blood hydralazine levels and response in hypertension.
Shepherd AM; Irvine NA; Ludden TM
Clin Pharmacol Ther; 1984 Jul; 36(1):14-8. PubMed ID: 6734044
[TBL] [Abstract][Full Text] [Related]
12. Determinants of response to intravenous hydralazine in hypertension.
Shepherd A; Lin MS; McNay J; Ludden T; Musgrave G
Clin Pharmacol Ther; 1981 Dec; 30(6):773-81. PubMed ID: 7307426
[TBL] [Abstract][Full Text] [Related]
13. The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status.
Rowell NP; Clark K
Radiother Oncol; 1990 Aug; 18(4):293-8. PubMed ID: 2244017
[TBL] [Abstract][Full Text] [Related]
14. The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.
Vandenburg MJ; Wright P; Holmes J; Rogers HJ; Ahmad RA
Br J Clin Pharmacol; 1982 May; 13(5):747-50. PubMed ID: 7082547
[No Abstract] [Full Text] [Related]
15. Effect of intravenous dose on hydralazine kinetics after administration.
Ludden TM; Shepherd AM; McNay JL; Lin MS
Clin Pharmacol Ther; 1983 Aug; 34(2):148-52. PubMed ID: 6872407
[TBL] [Abstract][Full Text] [Related]
16. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
Shen DD; Hosler JP; Schroder RL; Azarnoff DL
J Pharmacokinet Biopharm; 1980 Feb; 8(1):53-68. PubMed ID: 7381691
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
[TBL] [Abstract][Full Text] [Related]
19. Dihydralazine therapy and acetylator phenotype.
Iisalo E; Laine T; Lehtonen A; Sellman R
Int J Clin Pharmacol Biopharm; 1979 Mar; 17(3):119-24. PubMed ID: 429082
[TBL] [Abstract][Full Text] [Related]
20. Hydralazine in arterial hypertension. Randomized double-blind comparison of conventional/Slow-Release formulation and of b.i.d./q.i.d. dosage regimens.
Wulff K; Lenz K; Krogsgaard AR; Holst B
Acta Med Scand; 1980; 208(1-2):49-54. PubMed ID: 7435247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
